If you want to receive notifications of upcoming IPOs, you need to simply sign up or sign in with social networks.
Can you determine which companies are good and which ones - the trash?
Free Pro-version
IPO Filter
IPO today
Upcoming IPO
Biofrontera (BFRI)
Marpai (MRAI)
Cingulate, Inc. (CING)
Stronghold Digital Mining, Inc. (SDIG)
Enfusion, Inc. (ENFN)
Portillos Inc. (PTLO)
Winc, Inc. (BEV)
The Vita Coco Company, Inc. (COCO)
P10, Inc. (PX)
Ventyx Biosciences, Inc. (VTYX)
Winc, Inc. (WBEV)
Runway Growth Finance Corp (RWAY)
Aris Water Solutions, Inc. (ARIS)
Minerva Surgical, Inc (UTRS)
Xilio Therapeutics, Inc. (XLO)
Informatica Inc. (INFA)
Arteris, Inc. (AIP)
Priced IPO
Mink Therapeutics, Inc. (INKT)
Paragon 28, Inc. (FNA)
Ihs Holding Limited (IHS)
Gitlab Inc. (GTLB)
Lucid Diagnostics, Inc. (LUCD)
Healthcare Triangle (HCTI)
AvidXchange (AVDX)
Cognition Therapeutics, Inc. (CGTX)
Isoplexis Corporation (ISO)
Pyxis Oncology, Inc. (PYXS)
Life Time Group Holdings, Inc. (LTH)
Theseus Pharmaceuticals, Inc. (THRX)
Tricon Residential (TCN)
Volcon (VLCN)
Nuvei (NVEI)
Tdcx, Inc. (TDCX)
First Watch Restaurant Group, Inc. (FWRG)
Exscientia Limited (EXAI)
Warby Parker (WRBY)
Olaplex Holdings Inc. (OLPX)
More companies

Tscan Therapeutics, Inc. (TCRX)

Sector - Healthcare

Price chart

Return from IPO

Company News

IPO Profile

About company

Company Logo
They are a preclinical-stage biopharmaceutical company focused on developing a robust pipeline of T cell receptor-engineered T cell, or TCR-T, therapies for the treatment of patients with cancer. Their approach is based on the central premise that they can learn from patients who are winning their fight against cancer in order to treat those who are not. Using one of their proprietary platform technologies, TargetScan, they analyze the T cells of cancer patients with exceptional responses to immunotherapy to discover how the immune system naturally recognizes and eliminates tumor cells in these patients. This allows them to precisely identify the targets of T cell receptors, or TCRs, that are driving these exceptional responses. They aim to use these anti-cancer TCRs to treat patients with cancer by genetically engineering their own T cells to recognize and eliminate their cancer. In addition to discovering TCR-T therapies against novel targets, they are using their ReceptorScan technology to further diversify their portfolio of therapeutic TCRs with TCR-T therapies against known targets. They believe this two-pronged approach will enable them to discover and develop a wide array of potential treatment options for patients with cancer.
Biological Products (no Diagnostic Substances)
David Southwell Brian Silver
Employees Founded
64 2018


Address: 830 Winter Street Waltham, Massachusetts 02451

Telephone: (857) 399-9500

Web page:

IPO information

First Trade Date 7/16/2021
Status Priced
Exchange NASDAQ
Lockup Period Expiration .Pro
Quiet Period Expiration .Pro
Old Price Range
Share prices ($)

Shares & Volumes

Shares Initial (MM) 6.3
Shares Revised (MM) 6.67
Expected offer amount (MM) $100
Realized offer amount(MM) $100.05

Financial Data (last reporting year)

Market Cap (MM) $376.32
Revenues (MM) $3.09
Net Income (Loss) (MM) $-28.51


What do you think will happen with the TCRX share price after the next 3-6 months? 🔥 (+ 10% or more, flat (+ -10%), -10% or less)

Number of votes: img
The lead left underwriter: Morgan Stanley

IPOs led by the firm .Pro
Profitability of conducted IPOs  ?  .Pro
1st day change  ?  .Pro
Change for the first 3 months  ?  .Pro
Morgan Stanley/ Jefferies/ Cowen/ Barclays

Sector: Healthcare

Tweets about $TCRX

Tweets volume:

RT volume:


Google Trends Stats